BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Theragenics® Regains Compliance with NYSE Listing Standards


6/5/2009 9:55:20 AM

BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced it was notified by the New York Stock Exchange (the “NYSE”) that the Company is in compliance with the NYSE continued listing requirement pertaining to market capitalization and stockholders’ equity, as modified by the NYSE. This continued listing criterion, as modified, requires a company to maintain shareholders’ equity of at least $50 million if the company’s average market capitalization over a 30-day trading period is less than $50 million. Previously, the numeric thresholds in this requirement were $75 million. This modification is effective through October 31, 2009. The NYSE has stated that it anticipates a subsequent rule filing prior to October 31, 2009 to make this change a permanent continued listing standard. As of April 5, 2009, the completion of the Company’s most recent quarterly period, its stockholders’ equity totaled $74.9 million. As previously announced, Theragenics was notified by the NYSE on March 18, 2009 that it had fallen below compliance with the continued listing standards, as the Company’s stockholders’ equity, shareholders’ equity and market capitalization over 30 trading days was below $75 million.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES